Type 1 diabetes (T1D) is marked by debilitating degenerative complications on the long run due to chronic hyperglycemia.

Advanced glycation end-products seem to play a key role as potential biomarkers of vascular complications in diabetes.

We explored in a cross-sectional study the association between the circulating (i.e., carboxymethyllysine (CML), pentosidine, methylglyoxal–hydroimidazolone-1 (MGH1)) and tissue (i.e., skin autofluorescence (SAF)) advanced glycation end–products (AGEs) and the micro and macro vascular complications in 196 patients with T1D.

SAF and circulating AGEs display significant associations with micro and macrovascular complications in T1D.

SAF and circulating AGEs have potential therapeutic implications in T1D by identifying sub-populations of T1D requiring more aggressive treatment and monitoring to prevent vascular events.